The multi-year research collaboration will leverage LabGenius’ machine learning platform and LG Chem’s oncology expertise to develop tumour-selective antibodies addressing on-target, off-tumour toxicities in solid tumour treatment.
Drug discovery company LabGenius Therapeutics has entered into a multi-year research collaboration and licensing agreement with LG Chem to develop next-generation multispecific antibodies aimed at improving the treatment of difficult-to-treat cancers.
The partnership will focus on identifying novel antibody therapies designed to overcome some of the most significant limitations associated with current immunotherapies, particularly on-target, off-tumour toxicities that can lead to serious side effects in patients.
Under the agreement, the companies will work together to develop a tumour-selective therapeutic targeting a solid tumour antigen that is expressed across multiple cancer types. The programme is intended to generate more precise treatments capable of attacking cancer cells while reducing damage to healthy tissues.
The collaboration combines LabGenius’ artificial intelligence-driven drug discovery platform with LG Chem’s oncology development expertise in an effort to accelerate the identification of promising new therapeutic candidates.
AI-powered approach to antibody discovery
LabGenius has developed a platform that combines machine learning with high-throughput experimental capabilities to optimise therapeutic antibodies. The technology is designed to rapidly evaluate and refine potential drug candidates, helping researchers identify molecules with enhanced efficacy and safety profiles.
The company believes this approach is particularly well suited to the discovery of multispecific antibodies, which are engineered to engage multiple biological targets simultaneously and are increasingly viewed as a promising area of cancer drug development.
LabGenius has developed a platform that combines machine learning with high-throughput experimental capabilities to optimise therapeutic antibodies
“Partnering with LG Chem represents a very important moment for LabGenius and provides further validation of our platform’s ability to design highly optimised multispecific antibodies,” said Dr. James Field, CEO of LabGenius. “We welcome this opportunity to leverage our proprietary discovery capabilities to advance the development of safer and more effective immunotherapies for patients with solid tumours.”
Focus on high unmet medical need
Solid tumours remain among the most challenging forms of cancer to treat effectively, particularly when existing therapies produce significant toxicities or fail to deliver lasting responses.
LG Chem said the collaboration will focus on identifying oncology candidates capable of addressing these unmet medical needs through improved selectivity and reduced toxicity.
“LabGenius possesses a highly capable and systematic platform that enables rapid candidate exploration and early evaluation through a closed-loop structure integrating automated wet labs and computational dry labs,” said Jineon So, Head of R&D, Life Sciences Division at LG Chem. ”Through this collaboration, we aim to quickly identify novel oncology drug candidates with improved efficacy and reduced toxicity in areas of high unmet medical need.”
Pathway from discovery to development
Under the terms of the agreement, LabGenius will lead the programme through the early stages of preclinical research, including in vitro efficacy studies designed to assess the therapeutic potential of candidate molecules.
Following this phase, LG Chem will undertake additional preclinical development activities, including in vivo studies. The company will then have the option to acquire rights to the programme through an in-licensing agreement.
Under the terms of the agreement, LabGenius will lead the programme through the early stages of preclinical research
Financial details of the deal have not been disclosed. However, LabGenius will receive an upfront payment and may be eligible for early milestone payments. Should LG Chem exercise its licensing option, LabGenius could also receive potential triple-digit million-dollar clinical, regulatory and commercial milestone payments, in addition to royalties on future net sales.
LG Chem will fund all research and development activities carried out under the collaboration as the companies seek to move toward a new generation of targeted cancer therapies.
No comments yet